Osteoarthritis Pain - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：169頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Osteoarthritis Pain - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Osteoarthritis Pain - Pipeline Review, H1 2014’, provides an overview of the Osteoarthritis Pain’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Osteoarthritis Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Osteoarthritis Pain - Pipeline Review, H1 2014’, provides an overview of the Osteoarthritis Pain’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Osteoarthritis Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Osteoarthritis Pain Overview 8
Therapeutics Development 9
Pipeline Products for Osteoarthritis Pain - Overview 9
Pipeline Products for Osteoarthritis Pain - Comparative Analysis 10
Osteoarthritis Pain - Therapeutics under Development by Companies 11
Osteoarthritis Pain - Therapeutics under Investigation by Universities/Institutes 15
Osteoarthritis Pain - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Osteoarthritis Pain - Products under Development by Companies 20
Osteoarthritis Pain - Products under Investigation by Universities/Institutes 23
Osteoarthritis Pain - Companies Involved in Therapeutics Development 24
Johnson & Johnson 24
Allergan, Inc. 25
Sanofi 26
Eli Lilly and Company 27
BioDelivery Sciences International, Inc. 28
Purdue Pharma L.P. 29
Teva Pharmaceutical Industries Limited 30
A. Menarini Industrie Farmaceutiche Riunite Srl 31
Addex Therapeutics 32
Nuvo Research Inc. 33
Elite Pharmaceuticals, Inc. 34
Pozen, Inc. 35
Array BioPharma Inc. 36
Futura Medical plc 37
Transition Therapeutics Inc. 38
AcurePharma AB 39
Palau Pharma, S.A. 40
Neurotune AG 41
QRxPharma Limited 42
Iroko Pharmaceuticals, LLC 43
Winston Pharmaceuticals, Inc. 44
Antibe Therapeutics, Inc. 45
Flexion Therapeutics, Inc. 46
AllTranz, Inc. 47
Afferent Pharmaceuticals, Inc. 48
iCeutica, Inc. 49
Rottapharm|Madaus 50
Theralpha SAS 51
Creabilis SA 52
AbbVie Inc. 53
ARTYX Pharmaceuticals, Inc. 54
Akron Molecules GmbH 55
Osteoarthritis Pain - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Target 58
Assessment by Mechanism of Action 62
Assessment by Route of Administration 66
Assessment by Molecule Type 69
Drug Profiles 71
hydrocodone bitartrate ER - Drug Profile 71
duloxetine hydrochloride DR - Drug Profile 73
buprenorphine hydrochloride - Drug Profile 75
meloxicam nanoformulation - Drug Profile 77
zucapsaicin - Drug Profile 78
diclofenac nanoformulation - Drug Profile 80
ART-144 - Drug Profile 82
(oxycodone + naltrexone) - Drug Profile 83
ARRY-797 - Drug Profile 85
(morphine + oxycodone) CR - Drug Profile 87
AF-219 - Drug Profile 88
onabotulinumtoxinA - Drug Profile 90
SAR-292833 - Drug Profile 92
ABT-652 - Drug Profile 93
fasitibant chloride - Drug Profile 94
FX-005 - Drug Profile 95
LY-2828360 - Drug Profile 96
triamcinolone acetonide SR - Drug Profile 97
naproxen nanoformulation - Drug Profile 98
OLT-1177 - Drug Profile 100
grapiprant - Drug Profile 101
V-116517 - Drug Profile 103
AKR-202 - Drug Profile 104
(lidocaine + tetracaine) - Drug Profile 105
dimiracetam - Drug Profile 107
PA-65020 - Drug Profile 109
mavatrep - Drug Profile 110
AKR-203 - Drug Profile 111
ADX-71943 - Drug Profile 112
TASS - Drug Profile 113
zucapsaicin - Drug Profile 114
ADX-71441 - Drug Profile 116
CT-340 - Drug Profile 117
GABABR PAM - Drug Profile 118
THA-902 - Drug Profile 119
ATB-346 - Drug Profile 120
ibuprofen nanoformulation - Drug Profile 121
celecoxib nanoformulation - Drug Profile 122
THA-902 XL - Drug Profile 123
TASS Project - Drug Profile 124
TT-601 - Drug Profile 125
NEO-6860 - Drug Profile 126
A-889425 - Drug Profile 127
A-1048400 - Drug Profile 128
IPNIB - Drug Profile 129
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile 130
Small Molecules to Inhibit MMP-2/MMP-9 for Pain - Drug Profile 131
CRB-0022 - Drug Profile 132
Neogenius Project - Drug Profile 133
TPR-100-Rx - Drug Profile 134
CRB-0089 - Drug Profile 135
Cannabidiol Gel - Drug Profile 136
VLNX-4975 - Drug Profile 137
Osteoarthritis Pain - Recent Pipeline Updates 138
Osteoarthritis Pain - Dormant Projects 154
Osteoarthritis Pain - Discontinued Products 156
Osteoarthritis Pain - Product Development Milestones 157
Featured News & Press Releases 157
Appendix 164
Methodology 164
Coverage 164
Secondary Research 164
Primary Research 164
Expert Panel Validation 164
Contact Us 165
Disclaimer 165
List of Tables
Number of Products under Development for Osteoarthritis Pain, H1 2014 13
Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 16
Number of Products under Development by Companies, H1 2014 (Contd..1) 17
Number of Products under Development by Companies, H1 2014 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Development, H1 2014 22
Comparative Analysis by Unknown Stage Development, H1 2014 23
Products under Development by Companies, H1 2014 24
Products under Development by Companies, H1 2014 (Contd..1) 25
Products under Development by Companies, H1 2014 (Contd..2) 26
Products under Investigation by Universities/Institutes, H1 2014 27
Osteoarthritis Pain - Pipeline by Johnson & Johnson, H1 2014 28
Osteoarthritis Pain - Pipeline by Allergan, Inc., H1 2014 29
Osteoarthritis Pain - Pipeline by Sanofi, H1 2014 30
Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H1 2014 31
Osteoarthritis Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2014 32
Osteoarthritis Pain - Pipeline by Purdue Pharma L.P., H1 2014 33
Osteoarthritis Pain - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 34
Osteoarthritis Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 35
Osteoarthritis Pain - Pipeline by Addex Therapeutics, H1 2014 36
Osteoarthritis Pain - Pipeline by Nuvo Research Inc., H1 2014 37
Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals, Inc., H1 2014 38
Osteoarthritis Pain - Pipeline by Pozen, Inc., H1 2014 39
Osteoarthritis Pain - Pipeline by Array BioPharma Inc., H1 2014 40
Osteoarthritis Pain - Pipeline by Futura Medical plc, H1 2014 41
Osteoarthritis Pain - Pipeline by Transition Therapeutics Inc., H1 2014 42
Osteoarthritis Pain - Pipeline by AcurePharma AB, H1 2014 43
Osteoarthritis Pain - Pipeline by Palau Pharma, S.A., H1 2014 44
Osteoarthritis Pain - Pipeline by Neurotune AG, H1 2014 45
Osteoarthritis Pain - Pipeline by QRxPharma Limited, H1 2014 46
Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals, LLC, H1 2014 47
Osteoarthritis Pain - Pipeline by Winston Pharmaceuticals, Inc., H1 2014 48
Osteoarthritis Pain - Pipeline by Antibe Therapeutics, Inc., H1 2014 49
Osteoarthritis Pain - Pipeline by Flexion Therapeutics, Inc., H1 2014 50
Osteoarthritis Pain - Pipeline by AllTranz, Inc., H1 2014 51
Osteoarthritis Pain - Pipeline by Afferent Pharmaceuticals, Inc., H1 2014 52
Osteoarthritis Pain - Pipeline by iCeutica, Inc., H1 2014 53
Osteoarthritis Pain - Pipeline by Rottapharm|Madaus, H1 2014 54
Osteoarthritis Pain - Pipeline by Theralpha SAS, H1 2014 55
Osteoarthritis Pain - Pipeline by Creabilis SA, H1 2014 56
Osteoarthritis Pain - Pipeline by AbbVie Inc., H1 2014 57
Osteoarthritis Pain - Pipeline by ARTYX Pharmaceuticals, Inc., H1 2014 58
Osteoarthritis Pain - Pipeline by Akron Molecules GmbH, H1 2014 59
Assessment by Monotherapy Products, H1 2014 60
Assessment by Combination Products, H1 2014 61
Number of Products by Stage and Target, H1 2014 64
Number of Products by Stage and Mechanism of Action, H1 2014 68
Number of Products by Stage and Route of Administration, H1 2014 72
Number of Products by Stage and Molecule Type, H1 2014 74
Osteoarthritis Pain Therapeutics - Recent Pipeline Updates, H1 2014 142
Osteoarthritis Pain - Dormant Projects, H1 2014 158
Osteoarthritis Pain - Dormant Projects (Contd..1), H1 2014 159
Osteoarthritis Pain - Discontinued Products, H1 2014 160
List of Figures
Number of Products under Development for Osteoarthritis Pain, H1 2014 13
Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Products, H1 2014 22
Assessment by Monotherapy Products, H1 2014 60
Assessment by Combination Products, H1 2014 61
Number of Products by Top 10 Target, H1 2014 62
Number of Products by Stage and Top 10 Target, H1 2014 63
Number of Products by Top 10 Mechanism of Action, H1 2014 66
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 67
Number of Products by Top 10 Route of Administration, H1 2014 70
Number of Products by Stage and Top 10 Route of Administration, H1 2014 71
Number of Products by Top 10 Molecule Type, H1 2014 73
Number of Products by Stage and Top 10 Molecule Type, H1 2014 74
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Osteoarthritis Pain Overview 8
Therapeutics Development 9
Pipeline Products for Osteoarthritis Pain - Overview 9
Pipeline Products for Osteoarthritis Pain - Comparative Analysis 10
Osteoarthritis Pain - Therapeutics under Development by Companies 11
Osteoarthritis Pain - Therapeutics under Investigation by Universities/Institutes 15
Osteoarthritis Pain - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Osteoarthritis Pain - Products under Development by Companies 20
Osteoarthritis Pain - Products under Investigation by Universities/Institutes 23
Osteoarthritis Pain - Companies Involved in Therapeutics Development 24
Johnson & Johnson 24
Allergan, Inc. 25
Sanofi 26
Eli Lilly and Company 27
BioDelivery Sciences International, Inc. 28
Purdue Pharma L.P. 29
Teva Pharmaceutical Industries Limited 30
A. Menarini Industrie Farmaceutiche Riunite Srl 31
Addex Therapeutics 32
Nuvo Research Inc. 33
Elite Pharmaceuticals, Inc. 34
Pozen, Inc. 35
Array BioPharma Inc. 36
Futura Medical plc 37
Transition Therapeutics Inc. 38
AcurePharma AB 39
Palau Pharma, S.A. 40
Neurotune AG 41
QRxPharma Limited 42
Iroko Pharmaceuticals, LLC 43
Winston Pharmaceuticals, Inc. 44
Antibe Therapeutics, Inc. 45
Flexion Therapeutics, Inc. 46
AllTranz, Inc. 47
Afferent Pharmaceuticals, Inc. 48
iCeutica, Inc. 49
Rottapharm|Madaus 50
Theralpha SAS 51
Creabilis SA 52
AbbVie Inc. 53
ARTYX Pharmaceuticals, Inc. 54
Akron Molecules GmbH 55
Osteoarthritis Pain - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Target 58
Assessment by Mechanism of Action 62
Assessment by Route of Administration 66
Assessment by Molecule Type 69
Drug Profiles 71
hydrocodone bitartrate ER - Drug Profile 71
duloxetine hydrochloride DR - Drug Profile 73
buprenorphine hydrochloride - Drug Profile 75
meloxicam nanoformulation - Drug Profile 77
zucapsaicin - Drug Profile 78
diclofenac nanoformulation - Drug Profile 80
ART-144 - Drug Profile 82
(oxycodone + naltrexone) - Drug Profile 83
ARRY-797 - Drug Profile 85
(morphine + oxycodone) CR - Drug Profile 87
AF-219 - Drug Profile 88
onabotulinumtoxinA - Drug Profile 90
SAR-292833 - Drug Profile 92
ABT-652 - Drug Profile 93
fasitibant chloride - Drug Profile 94
FX-005 - Drug Profile 95
LY-2828360 - Drug Profile 96
triamcinolone acetonide SR - Drug Profile 97
naproxen nanoformulation - Drug Profile 98
OLT-1177 - Drug Profile 100
grapiprant - Drug Profile 101
V-116517 - Drug Profile 103
AKR-202 - Drug Profile 104
(lidocaine + tetracaine) - Drug Profile 105
dimiracetam - Drug Profile 107
PA-65020 - Drug Profile 109
mavatrep - Drug Profile 110
AKR-203 - Drug Profile 111
ADX-71943 - Drug Profile 112
TASS - Drug Profile 113
zucapsaicin - Drug Profile 114
ADX-71441 - Drug Profile 116
CT-340 - Drug Profile 117
GABABR PAM - Drug Profile 118
THA-902 - Drug Profile 119
ATB-346 - Drug Profile 120
ibuprofen nanoformulation - Drug Profile 121
celecoxib nanoformulation - Drug Profile 122
THA-902 XL - Drug Profile 123
TASS Project - Drug Profile 124
TT-601 - Drug Profile 125
NEO-6860 - Drug Profile 126
A-889425 - Drug Profile 127
A-1048400 - Drug Profile 128
IPNIB - Drug Profile 129
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile 130
Small Molecules to Inhibit MMP-2/MMP-9 for Pain - Drug Profile 131
CRB-0022 - Drug Profile 132
Neogenius Project - Drug Profile 133
TPR-100-Rx - Drug Profile 134
CRB-0089 - Drug Profile 135
Cannabidiol Gel - Drug Profile 136
VLNX-4975 - Drug Profile 137
Osteoarthritis Pain - Recent Pipeline Updates 138
Osteoarthritis Pain - Dormant Projects 154
Osteoarthritis Pain - Discontinued Products 156
Osteoarthritis Pain - Product Development Milestones 157
Featured News & Press Releases 157
Appendix 164
Methodology 164
Coverage 164
Secondary Research 164
Primary Research 164
Expert Panel Validation 164
Contact Us 165
Disclaimer 165
List of Tables
Number of Products under Development for Osteoarthritis Pain, H1 2014 13
Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 16
Number of Products under Development by Companies, H1 2014 (Contd..1) 17
Number of Products under Development by Companies, H1 2014 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Development, H1 2014 22
Comparative Analysis by Unknown Stage Development, H1 2014 23
Products under Development by Companies, H1 2014 24
Products under Development by Companies, H1 2014 (Contd..1) 25
Products under Development by Companies, H1 2014 (Contd..2) 26
Products under Investigation by Universities/Institutes, H1 2014 27
Osteoarthritis Pain - Pipeline by Johnson & Johnson, H1 2014 28
Osteoarthritis Pain - Pipeline by Allergan, Inc., H1 2014 29
Osteoarthritis Pain - Pipeline by Sanofi, H1 2014 30
Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H1 2014 31
Osteoarthritis Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2014 32
Osteoarthritis Pain - Pipeline by Purdue Pharma L.P., H1 2014 33
Osteoarthritis Pain - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 34
Osteoarthritis Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 35
Osteoarthritis Pain - Pipeline by Addex Therapeutics, H1 2014 36
Osteoarthritis Pain - Pipeline by Nuvo Research Inc., H1 2014 37
Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals, Inc., H1 2014 38
Osteoarthritis Pain - Pipeline by Pozen, Inc., H1 2014 39
Osteoarthritis Pain - Pipeline by Array BioPharma Inc., H1 2014 40
Osteoarthritis Pain - Pipeline by Futura Medical plc, H1 2014 41
Osteoarthritis Pain - Pipeline by Transition Therapeutics Inc., H1 2014 42
Osteoarthritis Pain - Pipeline by AcurePharma AB, H1 2014 43
Osteoarthritis Pain - Pipeline by Palau Pharma, S.A., H1 2014 44
Osteoarthritis Pain - Pipeline by Neurotune AG, H1 2014 45
Osteoarthritis Pain - Pipeline by QRxPharma Limited, H1 2014 46
Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals, LLC, H1 2014 47
Osteoarthritis Pain - Pipeline by Winston Pharmaceuticals, Inc., H1 2014 48
Osteoarthritis Pain - Pipeline by Antibe Therapeutics, Inc., H1 2014 49
Osteoarthritis Pain - Pipeline by Flexion Therapeutics, Inc., H1 2014 50
Osteoarthritis Pain - Pipeline by AllTranz, Inc., H1 2014 51
Osteoarthritis Pain - Pipeline by Afferent Pharmaceuticals, Inc., H1 2014 52
Osteoarthritis Pain - Pipeline by iCeutica, Inc., H1 2014 53
Osteoarthritis Pain - Pipeline by Rottapharm|Madaus, H1 2014 54
Osteoarthritis Pain - Pipeline by Theralpha SAS, H1 2014 55
Osteoarthritis Pain - Pipeline by Creabilis SA, H1 2014 56
Osteoarthritis Pain - Pipeline by AbbVie Inc., H1 2014 57
Osteoarthritis Pain - Pipeline by ARTYX Pharmaceuticals, Inc., H1 2014 58
Osteoarthritis Pain - Pipeline by Akron Molecules GmbH, H1 2014 59
Assessment by Monotherapy Products, H1 2014 60
Assessment by Combination Products, H1 2014 61
Number of Products by Stage and Target, H1 2014 64
Number of Products by Stage and Mechanism of Action, H1 2014 68
Number of Products by Stage and Route of Administration, H1 2014 72
Number of Products by Stage and Molecule Type, H1 2014 74
Osteoarthritis Pain Therapeutics - Recent Pipeline Updates, H1 2014 142
Osteoarthritis Pain - Dormant Projects, H1 2014 158
Osteoarthritis Pain - Dormant Projects (Contd..1), H1 2014 159
Osteoarthritis Pain - Discontinued Products, H1 2014 160
List of Figures
Number of Products under Development for Osteoarthritis Pain, H1 2014 13
Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Products, H1 2014 22
Assessment by Monotherapy Products, H1 2014 60
Assessment by Combination Products, H1 2014 61
Number of Products by Top 10 Target, H1 2014 62
Number of Products by Stage and Top 10 Target, H1 2014 63
Number of Products by Top 10 Mechanism of Action, H1 2014 66
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 67
Number of Products by Top 10 Route of Administration, H1 2014 70
Number of Products by Stage and Top 10 Route of Administration, H1 2014 71
Number of Products by Top 10 Molecule Type, H1 2014 73
Number of Products by Stage and Top 10 Molecule Type, H1 2014 74
